NK042 cell injection
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for NK042 cell injection, covering 2026-04-06 to 2026-04-22. Get the full timeline:
Most recent: Clinical Trial Update: An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS). [EARLY_Phase 1]